MX2017014344A - Metodos para el tratamiento de la inflacion o el dolor neuropatico. - Google Patents
Metodos para el tratamiento de la inflacion o el dolor neuropatico.Info
- Publication number
- MX2017014344A MX2017014344A MX2017014344A MX2017014344A MX2017014344A MX 2017014344 A MX2017014344 A MX 2017014344A MX 2017014344 A MX2017014344 A MX 2017014344A MX 2017014344 A MX2017014344 A MX 2017014344A MX 2017014344 A MX2017014344 A MX 2017014344A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- neuropathic pain
- treating inflammation
- inflammation
- treating
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 208000004296 neuralgia Diseases 0.000 title abstract 2
- 208000021722 neuropathic pain Diseases 0.000 title abstract 2
- 229940122357 Monoacylglycerol lipase inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento, se proporcionan métodos para tratar la inflamación o dolor neuropático, utilizando una dosis eficaz de un inhibidor de monoacilglicerol lipasa o una composición del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562159770P | 2015-05-11 | 2015-05-11 | |
US201662297670P | 2016-02-19 | 2016-02-19 | |
PCT/US2016/031668 WO2016183097A1 (en) | 2015-05-11 | 2016-05-10 | Methods of treating inflammation or neuropathic pain |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014344A true MX2017014344A (es) | 2018-04-11 |
Family
ID=57249499
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014344A MX2017014344A (es) | 2015-05-11 | 2016-05-10 | Metodos para el tratamiento de la inflacion o el dolor neuropatico. |
MX2021014815A MX2021014815A (es) | 2015-05-11 | 2017-11-08 | Metodos para el tratamiento de la inflamacion o el dolor neuropatico. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014815A MX2021014815A (es) | 2015-05-11 | 2017-11-08 | Metodos para el tratamiento de la inflamacion o el dolor neuropatico. |
Country Status (14)
Country | Link |
---|---|
US (3) | US10450302B2 (es) |
EP (1) | EP3294731A4 (es) |
JP (2) | JP2018515460A (es) |
KR (1) | KR20180004263A (es) |
CN (2) | CN113413387A (es) |
AU (3) | AU2016262459A1 (es) |
BR (1) | BR112017024253A2 (es) |
CA (1) | CA2984480A1 (es) |
EA (1) | EA201792496A1 (es) |
HK (1) | HK1252658A1 (es) |
IL (2) | IL255239A0 (es) |
MX (2) | MX2017014344A (es) |
SG (1) | SG10202012002TA (es) |
WO (1) | WO2016183097A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3326627A1 (en) | 2012-01-06 | 2018-05-30 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
EP3294731A4 (en) | 2015-05-11 | 2018-10-24 | Abide Therapeutics, Inc. | Methods of treating inflammation or neuropathic pain |
US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
DK3541807T3 (da) | 2016-11-16 | 2021-12-06 | H Lundbeck As | Krystallinsk form af en magl-inhibitor |
TN2019000148A1 (en) * | 2016-11-16 | 2020-10-05 | Abide Therapeutics Inc | Pharmaceutical formulations |
JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
WO2021214550A1 (en) * | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
US20210369704A1 (en) * | 2020-05-29 | 2021-12-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity |
WO2023192981A1 (en) * | 2022-03-31 | 2023-10-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating pancreatic diseases and disorders |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1593586A (es) | 1967-10-17 | 1970-06-01 | ||
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
WO1989011794A1 (en) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Plant growth inhibitor |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
WO1992018106A1 (en) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Method of manufacturing solid dispersion |
ATE195075T1 (de) | 1991-11-22 | 2000-08-15 | Procter & Gamble Pharma | Risedronat enthaltende arzneimittel mit verzögerter wirkstoffabgabe |
AU3226993A (en) | 1991-11-27 | 1993-06-28 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
JP2616252B2 (ja) | 1992-10-16 | 1997-06-04 | 日本新薬株式会社 | ワックスマトリックスの製法 |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
JPH09506920A (ja) | 1993-12-22 | 1997-07-08 | シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー | カルバメートの製造法 |
KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
EP0863879A1 (en) | 1995-11-15 | 1998-09-16 | Zeneca Limited | Herbicidal substituted pyrazole compounds |
AU3440597A (en) | 1996-07-02 | 1998-01-21 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
CA2386239A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying rna binding compounds |
EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
WO2003070247A1 (en) * | 2002-02-20 | 2003-08-28 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
AU2003300702A1 (en) | 2003-12-31 | 2005-07-21 | Council Of Scientific And Industrial Research | Process for preparing carbamates |
BRPI0507499A (pt) | 2004-02-18 | 2007-07-24 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5 |
WO2006066914A2 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
US7858609B2 (en) | 2005-11-28 | 2010-12-28 | Marinus Pharmaceuticals | Solid ganaxolone formulations and methods for the making and use thereof |
JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎の治療方法 |
CA2672172C (en) | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
EP1938804A1 (en) | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
JP2010519337A (ja) | 2007-02-26 | 2010-06-03 | コーサン バイオサイエンシーズ, インコーポレイテッド | カルバメート化合物 |
FR2938341A1 (fr) * | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
CA2730610A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and their use as gpcr modulators |
EP2373315A4 (en) | 2008-11-14 | 2012-06-27 | Scripps Research Inst | METHOD AND COMPOSITION RELATING TO TARGETING MONO-ACYLGLYCEROL LIPASE |
WO2010063802A1 (en) * | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
CN102548558B (zh) | 2009-03-23 | 2014-04-30 | Msdk.K.公司 | 具有Aurora A选择性抑制作用的氨基吡啶衍生物 |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
PL2497082T3 (pl) | 2009-11-03 | 2013-12-31 | Bayer Ip Gmbh | Fluorouretany jako dodatek w formulacji fotopolimerowej |
FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
AU2013207289B2 (en) | 2012-01-06 | 2017-09-21 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
EP3326627A1 (en) | 2012-01-06 | 2018-05-30 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
EP2828253A1 (en) * | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
EP2844247A4 (en) * | 2012-04-20 | 2015-11-25 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
JP6302923B2 (ja) | 2012-11-02 | 2018-03-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cftrが媒介する疾患の処置のための医薬組成物 |
US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
EP3294731A4 (en) | 2015-05-11 | 2018-10-24 | Abide Therapeutics, Inc. | Methods of treating inflammation or neuropathic pain |
JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
DK3541807T3 (da) | 2016-11-16 | 2021-12-06 | H Lundbeck As | Krystallinsk form af en magl-inhibitor |
JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
TN2019000148A1 (en) | 2016-11-16 | 2020-10-05 | Abide Therapeutics Inc | Pharmaceutical formulations |
-
2016
- 2016-05-10 EP EP16793377.9A patent/EP3294731A4/en not_active Withdrawn
- 2016-05-10 JP JP2017555626A patent/JP2018515460A/ja active Pending
- 2016-05-10 AU AU2016262459A patent/AU2016262459A1/en not_active Abandoned
- 2016-05-10 KR KR1020177035499A patent/KR20180004263A/ko not_active Application Discontinuation
- 2016-05-10 CN CN202110689840.3A patent/CN113413387A/zh active Pending
- 2016-05-10 SG SG10202012002TA patent/SG10202012002TA/en unknown
- 2016-05-10 MX MX2017014344A patent/MX2017014344A/es unknown
- 2016-05-10 US US15/573,272 patent/US10450302B2/en not_active Expired - Fee Related
- 2016-05-10 CN CN201680040975.4A patent/CN107849021A/zh active Pending
- 2016-05-10 WO PCT/US2016/031668 patent/WO2016183097A1/en active Application Filing
- 2016-05-10 CA CA2984480A patent/CA2984480A1/en not_active Abandoned
- 2016-05-10 BR BR112017024253A patent/BR112017024253A2/pt not_active Application Discontinuation
- 2016-05-10 EA EA201792496A patent/EA201792496A1/ru unknown
-
2017
- 2017-10-24 IL IL255239A patent/IL255239A0/en unknown
- 2017-11-08 MX MX2021014815A patent/MX2021014815A/es unknown
-
2018
- 2018-09-18 HK HK18111965.8A patent/HK1252658A1/zh unknown
-
2019
- 2019-09-06 US US16/563,733 patent/US11034674B2/en active Active
-
2020
- 2020-08-07 AU AU2020213382A patent/AU2020213382A1/en not_active Abandoned
-
2021
- 2021-04-09 US US17/227,072 patent/US20210230145A1/en not_active Abandoned
- 2021-06-22 IL IL284299A patent/IL284299A/en unknown
- 2021-09-28 JP JP2021158088A patent/JP2022008597A/ja active Pending
-
2022
- 2022-05-25 AU AU2022203543A patent/AU2022203543A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG10202012002TA (en) | 2021-01-28 |
US20210230145A1 (en) | 2021-07-29 |
US20200055841A1 (en) | 2020-02-20 |
CN113413387A (zh) | 2021-09-21 |
EP3294731A4 (en) | 2018-10-24 |
HK1252658A1 (zh) | 2019-05-31 |
WO2016183097A1 (en) | 2016-11-17 |
MX2021014815A (es) | 2022-01-18 |
AU2016262459A1 (en) | 2017-12-21 |
AU2022203543A1 (en) | 2022-06-16 |
AU2020213382A1 (en) | 2020-08-27 |
BR112017024253A2 (pt) | 2018-07-24 |
US10450302B2 (en) | 2019-10-22 |
JP2018515460A (ja) | 2018-06-14 |
US20180099951A1 (en) | 2018-04-12 |
KR20180004263A (ko) | 2018-01-10 |
US11034674B2 (en) | 2021-06-15 |
IL284299A (en) | 2021-07-29 |
CN107849021A (zh) | 2018-03-27 |
JP2022008597A (ja) | 2022-01-13 |
CA2984480A1 (en) | 2016-11-17 |
EP3294731A1 (en) | 2018-03-21 |
IL255239A0 (en) | 2017-12-31 |
EA201792496A1 (ru) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014815A (es) | Metodos para el tratamiento de la inflamacion o el dolor neuropatico. | |
PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
GB2541571A (en) | Pharmaceutical compositions | |
EP4069212A4 (en) | HIF-2 ALPHA INHIBITORS | |
MX2018001447A (es) | Bloqueadores de canal de ion cargado y metodos para su uso. | |
EP3906029A4 (en) | INHIBITORS OF MENIN-MLL INTERACTION | |
GB201804514D0 (en) | Treatment of pyroptosis | |
PH12019502548A1 (en) | Pyrazole magl inhibitors | |
IN2015DE00516A (es) | ||
SG10201908584SA (en) | Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease | |
MX2019002190A (es) | Uso de pridopidina para tratar distonías. | |
MX2019003069A (es) | Uso de pridopidina para tratar el sindrome de rett. | |
EP3609500A4 (en) | ADIPOCYTE TREATMENT | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
HK1256174A1 (zh) | 用於治療疼痛的 vap-1 抑制劑 | |
MX2018003301A (es) | Inhibidores de pcna. | |
GB201804515D0 (en) | Treatment of necroptosis | |
GB201506654D0 (en) | Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia | |
MX2017005064A (es) | Metodos para tratar afecciones oculares. | |
IL286938A (en) | Methods for treating neuropathic pain | |
MX2019006694A (es) | Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. | |
EP4054526A4 (en) | METHOD OF TREATMENT OF PALMÖBOT TEER KERATODERMA | |
GB201709136D0 (en) | New therapeutic uses of enzyme inhibitors | |
IL277962A (en) | Methods for treating neuropathic pain | |
EP3897642A4 (en) | METHODS OF TREATMENT OF INFLAMMATION |